BIOGRAPHICAL DATA DAMIEN FORREST GOLDBERG Address: Medical License: Board Certification: Wolstan & Goldberg Eye Associates 23600 Telo Ave Suite 100 Torrance, CA 90505 (310) 543-2611 California, Texas, and Washington, DC Diplomate of The American Board of Ophthalmology Recent Certificates and Awards: Diplomate of The United States Medical Licensing Examiners Fellow of the American Academy of Ophthalmology 2013 Co-Editor of Millennial Eye Electronic Periodical 2011 Certified for Ziemer femtosecond laser 2010 Chief of Ophthalmology Department, Torrance Memorial Medical Center 2010 Assistant Instructor, Jules Stein Eye Institute, UCLA 2008 Certified for Visx CustomVue Monovision 2007 Certified for Staar Implantable Contact Lens 2007 Certified for Allegretto Excimer Laser 2006 Certified for ReZoom Lens 2005 Certified for Cyrstalens 2005 Certified for Restor Lens 2005 Certifed fors Alcon LadarVision 2004 Certified for Visx Star 4 CustomVue and Fourier System 2004 Certified for Intralase 2003 William JG Davis MD Award, Washington National Eye Center Award for Resident Research Day Project 2003 Certificate of Appreciation by Washington Hospital Center for Glaucoma Screening 2002 Certificate of Completion Armed Forces Institutes of Pathology, Ophthalmic Pathology Professional Memberships: EDUCATION CEDARS Society Vanguard Ophthalmology Society American Congress of Ophthalmic Surgery American Academy of Ophthalmology American Society of Cataract and Refractive Surgeons American Society of Research in Vision and Ophthalmology
2004-2005 Cornea, External Disease and Refractive Surgery Fellow, Department of Ophthalmology University of Texas Southwestern Medical Center Dallas, TX 2001-2004 Resident, Department of Ophthalmology Georgetown University / Washington National Eye Center Washington, DC 2000-2001 Internship, Department of Internal Medicine Georgetown University Hospital Washington, DC 1995 2000 MD and MBA Georgetown University, School of Medicine and The Robert Emmett McDonough School of Business Awards: McKinsey & Company: Letter of Recognition from Washington Home for Health Care and Financial Consultation 1991-1995 Bachelor of Science, Anthropology and Human Biology Emory University Atlanta, GA Honors: Magna Cum Laude Lambda Alpha, Anthropology Honor Society Dean s List, 1992-1995 Past Employment 2000 Financial Analysis, McKinsey & Company (Affiliated with Georgetown School of Business) Designed a financial model for The Washington Home And Hospice Care 1999-2002. RECENT AND ACTIVE CLINICAL STUDIES: 1. Protocol CSP-002-03: A Prospective randomized controlled Multi-Center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) In Subjects with Preexisting Corneal Astigmatism.
2. EBI-005-03 A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/ml Topical Ophthalmic Solution versus Vehicle Control in Subjects with Moderate to Severe Dry Eye Disease (DED) 3. Protocol PPL GLAU M1: A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG) 4. Protocol M-13-19 Additive Effect of Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to Travoprost 5. C-11-018: A Prospective Clinical Study for Capsulotomy Using the Alcon Capsulotomy Device 6. 192024-041: An Open Label (Stage 1) and Randomized (Stage 2), 24-Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucomaor Ocular Hypertension. 7. 770: A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution With Timolol Maleate Ophthalmic Soultion 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension. 8. 801: Phase 3; A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Currently Active and Open Enrollment. 9. 195263-006: Phase 2; To evaluate the safety and efficacy of AGN-195263 (0.01%, 0.03%, and 0.1%) ophthalmic emulsion twice daily ocular topical administration compared to vehicle in patients with meibomian gland dysfunction (MGD). 10. A multi-center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution versus Placebo in Subjects with Dry Eye Syndrome. Study is finishing up, Not Enrolling anymore Subjects. 11. C-12-067: Phase 3: Randomized, Double-Masked, Vehicle- Controlled, Clinical Evaluation to Assess the Safety and Efficacy of Nepafanac 0.3% for prevention of Macular Edema following Cataract Surgery in Diabetic Retinopathy Patients. 12. M-13-019: Additive Effect of Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to Travoprost 13. EBI-005-1B A Phase 1, double-masked, placebo-controlled, escalating and repeat multidose study of the safety and tolerability of topically administered EBI-005 in healthy, adult subjects and in patients with moderate to severe dry eye disease. 14. C-10-040:Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/ml / Brimonidine 2 mg/mlfixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/ml Eye Drops, Suspension and Brimonidine 2 mg/ml Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
15. Clinical Investigation of AcrySof IQ Toric Intraocular Lens (IOL) Model SN6AT2. Protocol # C-09-076. The primary effectiveness objective of the study is to demonstrate higher percent reduction in cylinder in the IOL Model SN6AT2 group compared to the IOL Model SN60WF group in the study eye in either or both 0.50-0.74 D and 0.75-1.02 D astigmatism ranges at Visit 5 (120-180 days) postimplantation 16. Lifelong Vision Foundation, A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan ) versus 0.3% Hypromellose gel (Genteal gel ; placebo) for the Treatment of Adenovirus Conjunctivitis. Protocol # ADV-GAN-10-2011 17. A Device Evaluation Study to Further Assess the Physical and Clinical and Characteristics of Prototype Punctal Plug Design Iterations. Protocol # DEV 05. 18. A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L- PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG). Protocol # PPL GLAU 12 19. C-09-045: A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome. Protocol # C-10-033. 20. Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1 %/ Brimonidine 0.2% compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-Angle Glaucoma and/or Ocular Hypertension. Protocol # C- 09-45. 21. A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group Safety and Efficacy Study of Azithromcyin Ophthalmic Solution, 1% versus Vehicle in Subjects with Blepharitis. Protocol # 044-103: 22. Efficacy and Safety of X Ophthalmic Solution vs. Placebo for The Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. Protocol # S00124. 23. A Randomized, Masked, Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost Punctal Plug Delivery System (L-PPDS) and Comparing with that of Prostaglandin Eye Drops in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG). Protocol PPL GLAU 11. 24. A phase prospective, randomized observer masked, parallel-group, multi-centered study assessing the safety and efficacy of two concentrations of DE-110(0.6% and 0.1% SA22465) Compared to placebo for the treatment of dry eye disease Protocol # 30-002. 25. A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis
26. To evaluate the safety and efficacy of RESTASIS in reducing pterygium hyperemia, clinically assessed by the Pterygium Hyperemia Grading Scale at week 16 27. 044-103: A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel- Group Safety and Efficacy Study of Azithromcyin Ophthalmic Solution, 1% versus Vehicle in Subjects with Blepharitis 28. A Randomized, Multi-Center, Double-Masked, Placebo-Controlled, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Gel, 0.5% versus Vehicle for the Treatment of Inflammation and Pain following Cataract Surgery. 29. A One Year, Multicenter, Double-Masked, Randomized, Parallel-Group Study Assessing the Safety and Efficacy of Once Daily Application of Bimatoprost 0.03% Solution 30. A Randomized, Multi-Center, Double-Masked, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% versus Placebo for Two Weeks in Subjects with Blepharitis 31. Prospective Health Assessment of Cataract Patients Ocular Surface 32. The Clinical and Microbial efficacy of 0.6% ISV-403 compared to Vigamox in the treatment of bacterial conjunctivitis. 33. Phase II Assessing the Safety and Efficacy of Two Concentrations of DE-101 (0.002% and 0.006% Rivoglitazone HCL) Compared to Placebo for the Treatment of Dry Eye Disease. 34. A Randomized, Double-masked, Placebo- and Active- controlled, Parallel-group, Multicenter, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects with Primary Open-angle Glaucoma or Ocular Hypertension. 35. A multi-center Investigation of the Acceptability of LACRISERT in subjects with Dry Eyes. 36. A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale). 37. An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA. 38. Efficacy and Safety of Bromfenac Ophthalmic Solution QD vs. Placebo QD for Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. 39. Masked Comparison of Acular LS Plus Steriod versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients.
PUBLICATIONS: 1. Goldberg DF. Preoperative evaluation of patients before cataract and recractive surgery. Int Ophthalmol Clin. 2011 Spring;51(2):97-107. 2. Wittpenn J, Silverstein S, Hunkler J, Schechter B, Price F, Chu R, Wallace B, Trattler W, Dougherty P, Goldberg D, Perry H, Solomon K, Donnfeld E, Kenyon K, Roberts C. A Masked Comparison of Acular LS Plus Steriod versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients. Am J Ophthalmol. 2008 Oct;146(4):554-560. Epub 2008 Jul 2. 3. Petroll, WM, Goldberg DF, Lindsey SS, Kelley PS, MD, Cavanagh, DW, Bowman WR, Parmar DN, Verity SM, McCulley, JP. Confocal assessment of corneal response to intracorneal lens insertion and laser in situ keratomileusis with flap creation using IntraLase. Journal of Cataract & Refractive Surgery. 2006. Jul:32(7) 1119-28. 4. Goldberg DF. Implantation of the Phakic 6 H2 Intraocular Lens A Heparin-Coated Phakic Intraocular Lens. Techniques in Ophthalmology. 4(1):7-11, March 2006. 5. Goldberg DF, Negvesky G, Butrus S, Goodlick T. Ulcerative Keratitis in Mycosis Fungoides. Eye and Contact Lens. 2005. Sept; 31(5) 219-20. 6. Charters L, Goldberg D, Heparin-Coated IOL May Be Option for Myopic Patients. Ophthalmology Times March 15, 2005. p.57. 7. Kelley P, Awwad S, Goldberg D, Cavanagh D, Bowman W, Parmar D, Petroll M, Verity S, McCulley JP. Validation of Corneal Power Following LASIK Using Tomey Topographic Modeling System (TMS) in Pseudophakic Patients. Poster at ARVO Ft Lauderdale, FL. May 2005. 8. Goldberg D, Kelley P, Cavanagh D, Bowman W, Parmar D, Petroll M, Verity S, McCulley JP. Keratocyte Response Following INTACS, Intracorneal Lens Inserts, and Flap Creation by Femtosecond Laser Ablation (Intralase ) for LASIK. Poster at ARVO Ft Lauderdale, FL. May 2005. 9. Goldberg D, Panigrahi D, Butrus S, Abelson M. Case of Rofecoxib Associated Steven Johnson Syndrome with Corneal and Conjunctival Changes. Cornea 2004 Oct 23(7):736-737. 10. Scharper PH, Panigrahi D, Goldberg D, Barazi M, Deegan W. Phototoxicity From a High-Intensity Non-Laser Portable Light Source. Poster at ARVO Ft Lauderdale, FL. May 2003. 11. Boxer Wachler B, Huynh VA, El-Shiaty A, Goldberg D, Evaluation of corneal functional optical zone after laser in situ keratomileusis. Journal of Cataract & Refractive Surgery 2002; 28:948 953.
12. Goldberg D, Hillyer C, Investigations in the Re-Synovialization of Cadaveric Patellar tendon Allografts p.1-32. Emory Biology Department 1995. PRESENTATIONS: 1. Goldberg D. Laser Vision Correction. Presentation at Joint Commission on Allied Health Personnel in Ophthalmology, Inc. San Fransico, Ca Nov 2009. 2. Goldberg D. Laser Vision Correction. Presentation at Joint Commission on Allied Health Personnel in Ophthalmology, Inc. Atlanta, GA Nov 2008. 3. Goldberg D. Updates and Current Results of Multifocal and Toric Intraocular Lens. Presentation at SBOS Meeting El Segundo, CA May 2008 4. Goldberg D. Updates and Current Results of Multifocal and Toric Intraocular Lens. 3rd Annual Forever Young Symposium at Torrance Memorial Hospital Center. Torrance, CA Aug 2007 5. Goldberg D. Endothelial Keratoplasty (DLEK & DSEK): Current Techniques & Results. Presentation at SBOS Meeting Torrance, CA May 2007. 6. Goldberg, D. Peri-Operative Use of Steriods and Nonsteroidal Medication. Initial Results of A Masked Comparison of Acular LS Plus Steriod Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients. Roundtable Discussion sponsored by Allergan. Huntington Beach CA April 2007. 7. Goldberg D, Kelley P, Cavanagh D, Bowman W, Parmar D, Petroll M, Verity S, McCulley JP. Keratocyte response following refractive surgery with INTACS, PermaVision intracorneal lens inserts, and flap creation by Intralase femtosecond laser photodisruption for LASIK Presentation at American Society of Cataract and Refractive Surgery (ASCRS) Washington, DC April 2005. 8. Awwad S, Kelley P, Goldberg D, Cavanagh D, Bowman W, Parmar D, Petroll M, Verity S, McCulley JP. Validation of Corneal Power Following LASIK Using Tomey Topographic Modeling System (TMS) in Pseudophakic Patients. Presentation at ASCRS Washington, DC April 2005. 9. Portela R, Stoleru S, Goldberg D, Helfgott M., Butrus S. Pterygium Recurrence After Excision and Conjunctival Graft Fixation With Tissue Adhesive. 33 rd William JG Davis Resident Research Day, Georgetown/Washington National Eye, Jan. 2005. 10. Goldberg, D. Clinch T. Interim Results of the Phakic 6 TM H2 IOL Outcomes. Phakic IOLs Presentation at ASCRS San Diego, CA May, 2004. 11. Goldberg, D. Verhoeff Zimmerman Society Case of Endogenous Panophthalmitis Secondary to Clostridum septicum. Grand Rounds at Georgetown/Washington National Eye Center, Oct 2003. 12. Goldberg D, Bower, Case of Small Pox Vaccinia Keratitis at Walter Reed Medical Center. Grand Rounds at Georgetown/Washington National Eye Center, Feb. 2003.
13. Goldberg D. Central Corneal Thickness in African Americans and Caucasians with Primary Open Angle Glaucoma at the Washington National Eye Center. Winner at the 31 st William JG Davis Resident Research Day, Georgetown/Washington National Eye, Jan. 2003. 14. Goldberg D. Histiocytosis. Alper Neuro-Ophthalmology Series. Washington DC, Oct. 2002. 15. Goldberg D. Case Presentation and Therapy for Conjunctival Squamous Cell Carcinoma. Grand Rounds at Georgetown/Washington National Eye Center, Oct, 2002. 16. Goldberg D. Takayasu s Arteritis. Alper Neuro-Ophthalmology Series. Washington DC, Oct. 2001. PANELIST: Keratorefractive Flaps: Chu R, Daxer, A, Goldberg DF, Vryghem JC ASCRS 2009 San Francisico Ca. SKILLS & INTERESTS: Languages: -Spanish (Functional) Interests: -Surfing Golf, Running, Skiing, Kayaking, Traveling, Volunteer: -Friends of the Congressional Glaucoma Caucus Foundation, Screening 02-04 -Operation Smile, Volunteer Screening and Surgical Assistant 98 99